

**Author(s):**

**Question:**

**Setting:**

**Bibliography:** Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults (Review) Sutherland A, Naessens K, Plugge E, Ware L, Head K, Burton MJ, Wee B

Certainty assessment							No of patients		Effect		Certainty	Importance
No of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	olansapiini	platseebot	Relative (95% CI)	Absolute (95% CI)		

**livelduse ja oksendamise puudumine; olansapiin vs. platseebo/ no treatment (follow up: mean 5 days; assessed with: valideeritud iivelduse VAS skoor, väiksem number, vähem iiveldust))**

3 1,2,3	randomised trials	not serious	serious <sup>a</sup>	serious <sup>b</sup>	not serious	none	135/282 (47.9%)	70/279 (25.1%)	<b>RR 95.00</b> (1.59 to 2.47)	<b>1,000 more per 1,000</b> (from 148 more to 369 more)	⊕⊕○○ LOW	
------------	-------------------	-------------	----------------------	----------------------	-------------	------	-----------------	----------------	-----------------------------------	--	-------------	--

**Tõsised kõrvaltoimed; olanzapine vs. placebo/ no treatment (follow up: range 5 days to 8 weeks; assessed with: ekstrapüramidaalnähud, prolongeeritud QTc interval, neutropeenia ja agranulotsütoos, mõõdetud uuritavate hulgal, kui vähemalt üks neist sündmustest esinenud)**

7 1,2,3,4,5,6,7	randomised trials	not serious	serious <sup>c</sup>	serious <sup>b</sup>	serious <sup>c</sup>	none	5/446 (1.1%)	2/443 (0.5%)	<b>RR 2.46</b> (0.48 to 12.55)	<b>7 more per 1,000</b> (from 2 fewer to 52 more)	⊕○○○ VERY LOW	
--------------------	-------------------	-------------	----------------------	----------------------	----------------------	------	--------------	--------------	-----------------------------------	--	------------------	--

**Uimasus ja väsimus; olanzapin vs. platseebo/ no treatment (follow up: range 5 days to 8 weeks; assessed with: uimasuse ja väsimuse intsidendid uurimisperiodi vältel)**

5 3,4,5,6,8	randomised trials	serious <sup>d</sup>	not serious	not serious	not serious	none	30/232 (12.9%)	12/232 (5.2%)	<b>RR 2.33</b> (1.30 to 4.18)	<b>69 more per 1,000</b> (from 16 more to 164 more)	⊕⊕⊕○ MODERATE	
----------------	-------------------	----------------------	-------------	-------------	-------------	------	----------------	---------------	----------------------------------	--	------------------	--

**CI:** Confidence interval; **RR:** Risk ratio

#### Explanations

- The risk of nausea and vomiting in the control group varied from 19 % to 40 % . This variation was probably due to the characteristics of the trials being different (such as type of cancer, chemotherapy treatment given, dose of olanzapine etc)
- Enamus uuringuid CINV haigetel ( CINV- chemotherapy induced NV )
- There was only a small number of events (5 in olanzapine, 2 in control arm ) in one trial only. No events in either arm of six other trials leading to wide confidence intervals.
- There was unexplained heterogeneity in the risk of somnolence between studies making it difficult to be confident that the true effect lies close to the estimate of the effect.

#### References

- Lu Y L, Liu W, Du Y J, Feng L, Wang Y D, Wang L. Antiemetic effect of low dose olanzapine in solid tumor chemotherapy. . Chinese Journal of Cancer Prevention and Treatment ; 2013.
- Navari R, Qin R, Ruddy K, Liu H, Powell S, Bajaj M, et al. Navari R, Qin R, Ruddy K, Liu H, Powell S, Bajaj M, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double-blind, placebo-controlled trial. . Journal of Clinical Oncology; 2015.
- Mukhopadhyay S, Kwatra G, Alice K, Badyal D. Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study. . Supportive Care in Cancer; 2017.
- Zhao J, Li X, Jinghua G, Li Y, Li J, Shi Y, et al. Clinical observation of olanzapine for prevention of high and moderate emetic risk chemotherapy - induced nausea and vomiting. . Modern Oncology; 2014.
- D, Zhang. Aprepitant, olanzapine, palonosetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting. clinicaltrials.gov/ct2/show/NCT02484911; 2017.
- Navari R, Brenner M. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. . Supportive Care in Cancer ; 2010.
- Mizukami N, Yamauchi M, Koike K, Watanabe A, Ichihara K, Masumori N, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. . Journal of Pain and Symptom Management 2014; 2014.
- Wang X, Wang L, Wang H, Zhang H. Effectiveness of olanzapine combined with ondansetron in the prevention of chemotherapy-induced nausea and vomiting of non-small cell lung cancer. . Cell Biochemistry and Biophysics; 2015.